**eTable 1.** Summary of Inclusion/Exclusion Criteria Used for the Systematic Review

|  |  |  |
| --- | --- | --- |
|  | **Inclusion Criteria** | **Exclusion Criteria** |
| Population | Diagnosis of neovascular/wet AMD  Adults ≥18 years of age | Diagnosis of diabetic macular edema or retinal vein occlusion, or mixed population where the neovascular/wet AMD subgroup is not reported separately  Age <18 y |
| Intervention(s) | Any of the following using a T&E protocol:  Aflibercept (Eylea)  Ranibizumab (Lucentis)  Bevacizumab (Avastin) | No interventions of interest  No T&E protocol |
| Comparator(s) | Any, including placebo | No comparator |
| Outcomes | BCVA gains  Number of injections  Treatment interval | No outcomes of interest |
| Study type | Observational studies (ie, case-control, cohort)  Clinical trials (RCT and non-RCT)  SLRs with meta-analysis | Nonhuman studies  Case series/reports  Commentaries and letters  Recommendations/guidelines  Methods articles/protocols  Hypothetical models  Nonsystematic reviews |
| Other | English language only  Study size ≥100 eyes overall | Non-English language  Study size <100 eyes overall |

AMD indicates age-related macular degeneration; BCVA, best-corrected visual acuity; RCT, randomized controlled trial; SLR, systematic literature review; T&E, treat-and-extend.